VANCOUVER, British Columbia, June 30, 2017 /PRNewswire/ -- At the 2017 World Congress on Endometriosis (WCE), Dr. Hugh S. Taylor, MD, presented new research on how biomarkers could be used in the future of the diagnosis, management, and treatment of endometriosis.1 Dr. Taylor is the Chair of Obstetrics, Gynecology, and Reproductive Sciences at Yale School of Medicine, and the Chief Medical Officer and Founder of Dot Laboratories, a healthcare technology company.
Endometriosis is a chronic, estrogen-dependent, progesterone-resistant, inflammatory condition that causes dysmenorrhea and pelvic pain. Endometriosis is estimated to affect 35-50% of women with pelvic pain and infertility, or 176MM women and teens worldwide. The quality of life impact and economic burden are similar to chronic diseases including diabetes mellitus.2 Estimated U.S. costs for the diagnosis, treatment, and quality of life impact in 2009 totaled $69 billion USD.3
Today, physicians have limited options for the diagnosis and medical management of endometriosis. In a survey of 7,025 women with endometriosis,4 65% had previously been misdiagnosed, and 46% saw more than 5 MDs before getting to the correct diagnosis. In the U.S., the average timeframe from symptom onset to surgical diagnosis and treatment is 6.7-11 years.2 "With diagnostic biomarkers for endometriosis, the estimated 1 in 10 women affected by the disease could receive a correct diagnosis upon their first appointments with physicians," said Dr. Taylor.
Dr. Taylor presented data on candidates for biomarkers for endometriosis such as CA-125 and miRNAs1 during his presentation at the 13th World Congress on Endometriosis. Biomarkers of early detection and diagnosis could be used to detect or confirm the presence of the disease, offer diagnostic clarity or early diagnosis, and monitor asymptomatic individuals of high risk. The ideal diagnostic biomarker would assess both the presence of endometriosis and the characteristics of the disease. In a future with validated endometriosis biomarkers, physicians may be able to (1) shorten the delay to diagnosis of endometriosis in their patients and (2) offer medical treatment options that are supported by precision medicine to predict patient treatment response.
About the World Congress on Endometriosis: The WCE facilitates collaboration with its stakeholders and global partners to improve the lives of all affected women and their families. The goal of the WCE, held once every three years, is to advance evidence-based standards and innovations for education, advocacy, clinical care, and research in endometriosis and related disorders. For more information, please visit http://endometriosis.ca/world-congress/wce2017/.
About Dot Laboratories, Inc.: Dot Laboratories is a women's healthcare technology company based in San Francisco, CA and New Haven, CT. The company's first product in development, DotEndo, is a diagnostic test for endometriosis, a chronic condition that affects an estimated 1 in 10 women worldwide. For more information, please visit www.dotlab.com.
- Cosar E, et al. Fertil Steril. 2016;106(2):402–409.
- Nnoaham KE, et al. Fertil Steril. 2011;96(2):366–373.e8.
- Simoens S, et al. Hum Reprod. 2012;27(5):1292–1299.
- Mihalyi A, et al. Hum Reprod. 2010;25(3):654–664.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/chief-medical-officer-of-dot-laboratories-presents-biomarkers-at-the-13th-world-congress-on-endometriosis-300482737.html
SOURCE Dot Laboratories, Inc.